OC165: Shortcomings of serum CA125 in diagnosing ovarian cancer
نویسندگان
چکیده
منابع مشابه
CA125 in ovarian cancer.
A quarter of a century since its discovery, circulating CA125 antigen is recommended for clinical use in the USA for ovarian cancer screening of high-risk women with ovaries, despite its limited sensitivity and specificity. Recent findings suggest that CA125 might also serve as a predictive marker for pre-invasive ovarian carcinoma. Methods to quantify circulating CA125 evolved toward sensitive...
متن کاملThe significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer
BACKGROUND Ovarian cancer has the highest mortality rate of the three main malignant tumors of the female reproductive system, with a 5-year overall survival (OS) of only 20-30 %. Approximately 70 % of patients relapse without being cured. To explore the significance of serum CA125 level pre-treatment and the change pattern of CA125 post-treatment for judging prognosis and diagnosing recurrence...
متن کاملMeigs\' syndrome with elevated serum CA125 in a case of ovarian fibroma /thecoma
Abstract Background: CA125 levels in Meig’s syndrome can increase or be normal which an unusual laboratory condition is. In this paper, we present a case of Meigs’ syndrome associated with increased CA125 level due to ovarian fibroma / thecoma. Case presentation: A 50-year old Iranian woman presented with fever, abdominal pain and distention and in imaging assessment, a 90×109 mm heterogeneou...
متن کاملPersonalizing CA125 levels for ovarian cancer screening.
Screening trials for the early detection of ovarian cancer in the general population and in patients at a high risk for this disease have so far failed to show a reduction of ovarian cancer-specific mortality. Current screening modalities include pelvic examinations, transvaginal ultrasounds, and cancer antigen 125 (CA125) serum marker levels, which are associated with a high false-positive rat...
متن کاملMonitoring ovarian cancer: CA125 trial stirs controversy.
M onitoring ovarian cancer with regular blood tests for the CA125 biomarker is a firmly embedded practice in oncology, the theory being that rising CA125 levels may indicate a recurrence, which can be treated effectively upon early detection. But results from a new randomized, controlled trial presented at the annual meeting of the American Association of Clinical Oncology (ASCO) earlier this y...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Ultrasound in Obstetrics and Gynecology
سال: 2006
ISSN: 0960-7692
DOI: 10.1002/uog.3025